動脈硬化治療薬の世界市場レポート 2025年

動脈硬化治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR3.7％で593億8,000万米ドルに成長します。予測期間の成長は、新たな治療法、精密医療、免疫療法と炎症、脂質管理の革新、規制支援に起因すると考えられます。予測期間の主な動向には、生物学的療法、遺伝子編集と遺伝子治療、併用療法、個別化治療アプローチ、遠隔医療と遠隔モニタリングが含まれます。

心血管疾患の有病率の増加は、今後のアテローム性動脈硬化症治療薬市場の成長を促進すると予想されます。心血管疾患は、心臓や血管に影響を与えるすべての状態を包括していますが、動脈硬化は特に、動脈壁に沿った脂肪、コレステロール、その他の物質の蓄積を伴います。動脈にプラークが蓄積すると、冠動脈性心疾患や脳卒中などの心血管疾患につながります。動脈硬化治療薬は、合併症のリスクを減らし、高コレステロール値や血栓形成などの根本的な要因に対処することで、心血管疾患を管理するために投与されます。例えば、2024年9月に米国の州保健機関であるミネソタ州保健局が発表したデータによると、2023年にはミネソタ州の成人の約30％が高血圧を報告し、約140万人が影響を受けています。さらに、高血圧性疾患は2022年に14,225人の住民の主な死因または死因の一因となり、同州の全死亡者の約28％を占めました。その結果、心血管疾患の有病率の上昇は、アテローム性動脈硬化症治療薬市場を促進するでしょう。

高齢化人口の増加は、今後数年間のアテローム性動脈硬化症治療薬市場の成長を促進すると予想されています。高齢化とは、社会における高齢者の割合や数の大幅な増加を特徴とする人口動態を指します。動脈硬化治療薬は、心血管系リスクの高まりに対応し、予防、管理、治療において重要な役割を果たし、健康全般をサポートするため、高齢者にとって不可欠なものです。例えば、米国に本部を置く国連事務局の経済社会局（UN DESA）は2023年1月、65歳以上の世界人口が2倍以上に増加し、2021年の7億6,100万人から2050年には16億人になると予測しました。このように、高齢化人口の拡大が動脈硬化治療薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界動脈硬化治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の動脈硬化治療薬市場：成長率分析
• 世界の動脈硬化治療薬市場の実績：規模と成長, 2019-2024
• 世界の動脈硬化治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界動脈硬化治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の動脈硬化治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血小板薬
• フィブリン酸とオメガ3脂肪酸誘導体
• アンジオテンシンカバー酵素（ACE）阻害剤
• 利尿剤
• コレステロール低下薬
• ベータ遮断薬
• カルシウムチャネル遮断薬
• その他の薬物クラス
• 世界の動脈硬化治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• 世界の動脈硬化治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル
• 世界の動脈硬化治療薬市場抗血小板薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アスピリン
• クロピドグレル
• チカグレロル
• 世界の動脈硬化治療薬市場、フィブリン酸およびオメガ3脂肪酸誘導体の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェノフィブラート
• ゲムフィブロジル
• オメガ3脂肪酸サプリメント
• 世界の動脈硬化治療薬市場アンジオテンシン結合酵素（ACE）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リシノプリル
• エナラプリル
• ラミプリル
• 世界の動脈硬化治療薬市場利尿薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• チアジド系利尿薬
• ループ利尿薬
• カリウム保持性利尿薬
• 世界の動脈硬化治療薬市場コレステロール低下薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• スタチン
• PCSK9阻害剤
• 胆汁酸捕捉剤
• 世界の動脈硬化治療薬市場、ベータ遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトプロロール
• アテノロール
• カルベジロール
• 世界の動脈硬化治療薬市場カルシウムチャネル遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アムロジピン
• ジルチアゼム
• ベラパミル
• 世界の動脈硬化治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗凝固剤
• 血管拡張薬
• コレステロール吸収阻害剤

第7章 地域別・国別分析

• 世界の動脈硬化治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の動脈硬化治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 動脈硬化治療薬市場：競合情勢
• 動脈硬化治療薬市場：企業プロファイル
  • Johnson And Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Janssen Pharmaceuticals Inc.
• Novartis AG
• Merck And Co.Inc.
• Sanofi S.A.
• AstraZeneca plc
• Abbott Laboratories
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 動脈硬化治療薬市場2029：新たな機会を提供する国
• 動脈硬化治療薬市場2029：新たな機会を提供するセグメント
• 動脈硬化治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Atherosclerosis drugs are medications employed for the management and treatment of atherosclerosis, a condition characterized by the accumulation of plaque in the arteries. The objectives of drug treatment for atherosclerosis include reducing plaque formation, slowing its progression, and addressing risk factors associated with the development of atherosclerosis.

The primary categories of atherosclerosis drugs encompass anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, angiotensin-covering enzyme (ACE) inhibitors, diuretics, cholesterol-lowering medications, beta-blockers, calcium channel blockers, and other related medications. Antiplatelet medications are drugs that hinder the formation of blood clots by impeding the aggregation of platelets, which are small cell fragments in the blood. These drugs can be administered orally or through injections and are primarily dispensed through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others.

The atherosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides atherosclerosis drugs market statistics, including atherosclerosis drugs industry global market size, regional shares, competitors with an atherosclerosis drugs market share, detailed atherosclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the atherosclerosis drugs industry. This atherosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The atherosclerosis drugs market size has grown steadily in recent years. It will grow from $49.89 billion in 2024 to $51.42 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to cholesterol management, blood pressure control, smoking cessation programs, research and development, diagnostic advancements

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $59.38 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to emerging therapies, precision medicine, immunotherapy and inflammation, innovations in lipid management, regulatory support. Major trends in the forecast period include biologic therapies, gene editing and gene therapy, combination therapies, personalized treatment approaches, telemedicine and remote monitoring.

The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the atherosclerosis drug market in the future. Cardiovascular diseases encompass all conditions that impact the heart and blood vessels, while atherosclerosis specifically involves the accumulation of fats, cholesterol, and other substances along artery walls. This plaque buildup in the arteries leads to cardiovascular issues, including coronary heart disease and stroke. Atherosclerosis drugs are administered to manage cardiovascular diseases by reducing the risk of complications and addressing underlying factors such as high cholesterol levels and blood clot formation. For instance, in September 2024, data released by the Minnesota Department of Health, a US-based state health agency, indicated that around 30% of adults in Minnesota reported high blood pressure in 2023, affecting nearly 1.4 million individuals. Additionally, hypertensive diseases were the primary or contributing cause of death for 14,225 residents in 2022, accounting for nearly 28% of all deaths in the state. Consequently, the rising prevalence of cardiovascular diseases will propel the atherosclerosis drug market.

The increasing aging population is anticipated to drive the growth of the atherosclerosis drug market in the coming years. An aging population refers to a demographic trend marked by a substantial rise in the proportion or number of elderly individuals within a society. Atherosclerosis drugs are essential for the elderly, as they address heightened cardiovascular risks and play a critical role in prevention, management, and treatment to support overall health. For example, in January 2023, the United Nations Department of Economic and Social Affairs (UN DESA), a U.S.-based department of the UN Secretariat, projected that the global population aged 65 and older will more than double, increasing from 761 million in 2021 to 1.6 billion by 2050. Thus, the expanding aging population is driving the growth of the atherosclerosis drug market.

Product innovation is a prominent trend gaining momentum in the atherosclerosis drugs market. Leading companies in the market are developing innovative drugs and obtaining approvals to maintain their competitive edge. For example, in March 2024, Novo Nordisk A/S, a Denmark-based healthcare company, announced the approval of Wegovy (semaglutide) for reducing cardiovascular risk in individuals with overweight or obesity. This is the first weight loss medication approved to lower the risk of major cardiovascular events in adults with obesity or overweight and established cardiovascular disease, offering a new therapeutic option for this high-risk group. This dual functionality not only supports obesity management but also helps prevent serious cardiovascular complications, potentially enhancing patient outcomes and longevity.

Leading companies in the atherosclerosis drugs market are developing anti-inflammatory drugs to boost profitability and market share. Anti-inflammatory drugs for atherosclerosis aim to reduce inflammation linked to plaque buildup in arteries, a hallmark of the disease. For instance, in June 2023, AGEPHA Pharma, a Europe-based medical product manufacturer, launched LODOCO. LODOCO (colchicine, 0.5 mg tablet) received approval from the U.S. FDA as the first anti-inflammatory atheroprotective treatment for cardiovascular care. The drug effectively reduces the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. By targeting residual inflammation, a critical factor in atherosclerotic cardiovascular disease (ASCVD), LODOCO can be used independently or alongside cholesterol-lowering medications, marking a significant advancement in cardiovascular treatment.

In April 2023, Chiesi Farmaceutici S.p.A., an Italian pharmaceutical company, completed the acquisition of Amryt Pharma plc for an approximate sum of $1.25 billion. This strategic move aims to expand Chiesi Farmaceutici S.p.A.'s rare disease portfolio, gain access to Amryt's pipeline of developmental candidates, and establish a presence in the US market. Amryt Pharma plc, based in Ireland, specializes in the development of atherosclerosis drugs for the treatment of rare diseases, including atherosclerosis and generalized lipodystrophies.

Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the atherosclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The atherosclerosis drugs market consists of sales of statins, rosuvastatin, atorvastatin, fibrates, bile acid sequestrants, nitrates, ezetimibe, and blood pressure medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atherosclerosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atherosclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atherosclerosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atherosclerosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Anti-Platelet Medications; Fibric Acid And Omega-3 Fatty Acid Derivatives; Angiotensin-Covering Enzyme (ACE) Inhibitors; Diuretics; Cholesterol Lowering Medication; Beta Blockers; Calcium Channel Blockers; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Anti-Platelet Medications: Aspirin; Clopidogrel; Ticagrelor
• 2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate; Gemfibrozil; Omega-3 Fatty Acid Supplements
• 3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril; Enalapril; Ramipril
• 4) By Diuretics: Thiazide Diuretics; Loop Diuretics; Potassium-Sparing Diuretics
• 5) By Cholesterol Lowering Medication: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants
• 6) By Beta Blockers: Metoprolol; Atenolol; Carvedilol
• 7) By Calcium Channel Blockers: Amlodipine; Diltiazem; Verapamil
• 8) By Other Drug Classes: Anticoagulants; Vasodilators; Cholesterol Absorption Inhibitors
• Companies Mentioned: Johnson And Johnson Private Limited; Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Atherosclerosis Drugs Market Characteristics

3. Atherosclerosis Drugs Market Trends And Strategies

4. Atherosclerosis Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Atherosclerosis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Atherosclerosis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Atherosclerosis Drugs Market Growth Rate Analysis
• 5.4. Global Atherosclerosis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Atherosclerosis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Atherosclerosis Drugs Total Addressable Market (TAM)

6. Atherosclerosis Drugs Market Segmentation

• 6.1. Global Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Platelet Medications
• Fibric Acid And Omega-3 Fatty Acid Derivatives
• Angiotensin-Covering Enzyme (ACE) Inhibitors
• Diuretics
• Cholesterol Lowering Medication
• Beta Blockers
• Calcium Channel Blockers
• Other Drug Classes
• 6.2. Global Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.4. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Anti-Platelet Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aspirin
• Clopidogrel
• Ticagrelor
• 6.5. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Fibric Acid And Omega-3 Fatty Acid Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fenofibrate
• Gemfibrozil
• Omega-3 Fatty Acid Supplements
• 6.6. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Angiotensin-Covering Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lisinopril
• Enalapril
• Ramipril
• 6.7. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thiazide Diuretics
• Loop Diuretics
• Potassium-Sparing Diuretics
• 6.8. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Cholesterol Lowering Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• PCSK9 Inhibitors
• Bile Acid Sequestrants
• 6.9. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metoprolol
• Atenolol
• Carvedilol
• 6.10. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amlodipine
• Diltiazem
• Verapamil
• 6.11. Global Atherosclerosis Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticoagulants
• Vasodilators
• Cholesterol Absorption Inhibitors

7. Atherosclerosis Drugs Market Regional And Country Analysis

• 7.1. Global Atherosclerosis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Atherosclerosis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Atherosclerosis Drugs Market

• 8.1. Asia-Pacific Atherosclerosis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Atherosclerosis Drugs Market

• 9.1. China Atherosclerosis Drugs Market Overview
• 9.2. China Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Atherosclerosis Drugs Market

• 10.1. India Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Atherosclerosis Drugs Market

• 11.1. Japan Atherosclerosis Drugs Market Overview
• 11.2. Japan Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Atherosclerosis Drugs Market

• 12.1. Australia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Atherosclerosis Drugs Market

• 13.1. Indonesia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Atherosclerosis Drugs Market

• 14.1. South Korea Atherosclerosis Drugs Market Overview
• 14.2. South Korea Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Atherosclerosis Drugs Market

• 15.1. Western Europe Atherosclerosis Drugs Market Overview
• 15.2. Western Europe Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Atherosclerosis Drugs Market

• 16.1. UK Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Atherosclerosis Drugs Market

• 17.1. Germany Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Atherosclerosis Drugs Market

• 18.1. France Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Atherosclerosis Drugs Market

• 19.1. Italy Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Atherosclerosis Drugs Market

• 20.1. Spain Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Atherosclerosis Drugs Market

• 21.1. Eastern Europe Atherosclerosis Drugs Market Overview
• 21.2. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Atherosclerosis Drugs Market

• 22.1. Russia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Atherosclerosis Drugs Market

• 23.1. North America Atherosclerosis Drugs Market Overview
• 23.2. North America Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Atherosclerosis Drugs Market

• 24.1. USA Atherosclerosis Drugs Market Overview
• 24.2. USA Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Atherosclerosis Drugs Market

• 25.1. Canada Atherosclerosis Drugs Market Overview
• 25.2. Canada Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Atherosclerosis Drugs Market

• 26.1. South America Atherosclerosis Drugs Market Overview
• 26.2. South America Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Atherosclerosis Drugs Market

• 27.1. Brazil Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Atherosclerosis Drugs Market

• 28.1. Middle East Atherosclerosis Drugs Market Overview
• 28.2. Middle East Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Atherosclerosis Drugs Market

• 29.1. Africa Atherosclerosis Drugs Market Overview
• 29.2. Africa Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Atherosclerosis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Atherosclerosis Drugs Market Competitive Landscape
• 30.2. Atherosclerosis Drugs Market Company Profiles
  • 30.2.1. Johnson And Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Atherosclerosis Drugs Market Other Major And Innovative Companies

• 31.1. Janssen Pharmaceuticals Inc.
• 31.2. Novartis AG
• 31.3. Merck And Co.Inc.
• 31.4. Sanofi S.A.
• 31.5. AstraZeneca plc
• 31.6. Abbott Laboratories
• 31.7. GSK plc.
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Eli Lilly and Company
• 31.10. Gilead Sciences Inc.
• 31.11. Amgen Inc.
• 31.12. Novo Nordisk A/S
• 31.13. Boehringer Ingelheim International GmbH
• 31.14. Viatris Inc.
• 31.15. Teva Pharmaceutical Industries Ltd.

32. Global Atherosclerosis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Atherosclerosis Drugs Market

34. Recent Developments In The Atherosclerosis Drugs Market

35. Atherosclerosis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Atherosclerosis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Atherosclerosis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Atherosclerosis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer